Gilvetmab is the first and only immune checkpoint inhibitor developed for the treatment of mast cell tumors (MCTs) and melanomas in dogs.
LEARN MOREFor the prevention of early mortality in day-old chickens associated with Escherichia coli, Salmonella typhimurium, and Pseudomonas aeruginosa
LEARN MOREFor the prevention and treatment of Selenium-Tocopherol Deficiency (white muscle disease) syndrome in calves.
LEARN MORE